Pricing Log in Create free account
Friday 6 November 2026 Export CSTL’s income statement to Excel — free account

Castle Biosciences, Inc.

CSTL Healthcare Diagnostics & Research

Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024.

Revenue
+23.9%
EPS
−550.0%
Free cash flow
+56.8%
Total debt
−59.9%

Quarter to September 2026, against a year earlier

32.08 2.12 −6.20%
Market cap
$1.0B
P/E
0.0×
Fwd P/E
−29.8×
Dividend yield
—
F-score
3/9
Altman Z
6.70
Beneish M
−3.49
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 18.13
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 8 2 1 8 2 2 3 6 9 5 6 1
Insider Ownership 2.26%

Capital & Financial Ratios $m

Size
Market Cap 1,040.00
Revenue ttm 377.13
Net income ttm (23.01)
Free cash flow ttm 3.99
Net debt Q 4.17
Valuation
P/E 0.00
Forward P/E (29.80) (negative: loss-making)
Price / sales 2.77
Forward P/S Powerpack
Price / FCF 262.33
Price / book 2.19
Financial health
Current ratio Q 5.28 (at or above 1.5: strong)
Debt / equity Q 0.01 (at or below 0.5: strong)
Interest coverage Q (13.86)
Growth
Revenue growth Q +23.90% (above 0%: growing)
Operating income growth Q +59.86% (above 0%: growing)
EPS, this year −44.70% (below 0%: weak)
EPS, next year A +27.34% (at or above 15%: strong)
Revenue, next year A +8.68%
EPS, past 5 yrs —
EPS, next 5 yrs A +25.22% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.1×, against a ten-year median of 2.5×; over the ten years it ranged from 0.5× in 2025 to 20.2× in 2021.
P/S against its own 10 years 37.06%
10-year low 10-year high
P/B against its own 10 years 60.30%
10-year low 10-year high
EV/Sales against its own 10 years 44.21%
10-year low 10-year high
EV/FCF against its own 10 years 88.05%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 243 293 300 —
Receivables 38 51 43 52
Inventory 8 8 10 10
Other — — — —
296 360 361 357
2023 2024 2025 Q'26
Payables 10 7 19 13
ST’ Debt — 0 0 4
Other — — 1 —
48 49 69 68

Compound Annual Growth %

10y 5y 3y
Sales — 40.60% 35.94%
Cash Flow — 45.51% 0.00%
Earnings — 0.00% 0.00%
Book Value — 2.52% 5.66%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.44 Actual −0.07

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.34 −0.02 Beat by 0.32
Q4 FY25 −0.23 −0.08 Beat by 0.15
Q1 FY26 −0.56 −0.49 Beat by 0.07
Q2 FY26 −0.44 −0.07 Beat by 0.37
Q3 FY26 −0.38 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.49) (0.07) (0.13) — —
’25 (0.90) 0.15 (0.02) (0.08) (0.83)
’24 (0.09) 0.31 0.08 0.32 0.62
’23 (1.10) (0.70) (0.26) (0.10) (2.14)
’22 (0.97) (0.06) (0.77) (0.78) (2.58)
’21 (0.17) (0.35) (0.47) (0.25) (1.24)
’20 0.03 (0.08) (0.23) (0.23) (0.54)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 84 104 103 — —
’25 88 86 83 87 344
’24 73 87 86 86 332
’23 42 50 61 66 220
’22 27 35 37 38 137
’21 23 23 23 25 94
’20 17 13 15 17 63
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) 15 20 — —
’25 (6) 21 23 27 64
’24 (7) 24 23 24 65
’23 (25) (4) 5 19 (6)
’22 (21) (9) (5) (6) (42)
’21 (4) (6) (6) (3) (19)
’20 0 14 (3) 0 10
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (35) 7 12 — —
’25 (11) 12 8 20 28
’24 (16) 19 17 17 37
’23 (29) (8) 3 15 (19)
’22 (22) (10) (7) (8) (47)
’21 (4) (7) (7) (4) (22)
’20 (1) 12 (5) (1) 5
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 14 23 52 63 94 137 220 332 344 377 +49.6% 374 419 478 +11.5%
Gross margin, % — 63.33 76.75 85.91 84.54 83.18 76.64 79.53 81.87 79.37 77.07 +16.0 pt
EBT — (12) (6) 5 (10) (40) (69) (57) 22 (30) (23) +11.5%
EBT margin, % — (89.86) (27.90) 10.31 (16.28) (42.53) (50.28) (26.10) 6.49 (8.57) (6.00) +81.3 pt
Net income — 0 (6) 5 (10) (31) (67) (57) 18 (24) (23) n/m
Per share, $
Per share, $ Revenue — 0.83 11.95 6.04 3.31 3.74 5.26 8.20 11.96 11.88 12.31 +39.5%
Earnings — (0.92) (5.33) 0.35 (0.54) (1.24) (2.58) (2.14) 0.66 (0.83) (0.77) (1.3%)
Cash flow — (0.73) (6.45) 0.82 0.52 (0.76) (1.60) (0.21) 2.34 2.22 1.30 n/m
Capex — 0.00 (0.15) (0.11) (0.25) (0.14) (0.21) (0.51) (1.02) (1.24) (1.17) n/m
Free cash flow — (0.73) (6.60) 0.71 0.27 (0.89) (1.81) (0.72) 1.32 0.98 0.13 n/m
Book value — (0.95) (29.68) 9.92 21.96 16.38 15.32 14.60 16.41 16.24 15.62 n/m
Shares, m — 17 2 9 19 25 26 27 28 29 30 +7.2%
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 41.00 0.00 0.00 4.6
P/S — 1.70 1.70 5.69 20.29 11.45 4.33 2.68 2.23 3.28 2.77 5.9
P/B — 0.00 0.00 3.47 3.06 2.62 1.49 1.50 1.62 2.39 2.19 1.8
EV/Sales — 1.96 1.96 4.27 14.11 8.04 2.54 1.64 1.38 2.44 2.10 4.3
EV/FCF — (13.90) (13.90) 36.41 172.70 (33.67) (7.39) (18.72) 12.51 29.55 198.35 18.2
Cash, $m
Cash, $m Operating cash flow — (12) (12) 7 10 (19) (42) (6) 65 64 40 n/m
Capex — 0 0 (1) (5) (3) (5) (14) (28) (36) (36) +70.9%
Free cash flow — (12) (13) 6 5 (22) (47) (19) 37 28 4 n/m
Balance, $m
Balance, $m Working capital — 1 11 101 409 329 256 248 311 292 289 +93.9%
Net debt — 19 20 (74) (410) (322) (245) (243) (283) (289) 4 n/m
Shareholders’ equity — (16) (57) 85 416 412 399 391 456 471 478 n/m
Returns, %
Returns, % ROA — (95.00) (90.72) 4.21 (3.68) (6.94) (14.76) (12.76) 3.71 (4.35) (4.03) +90.6 pt
ROIC — 0.00 0.00 40.21 (70.02) (27.78) (29.60) (28.67) 3.13 (14.72) (3.63) (14.7) pt
ROE — 28.65 19.02 20.95 (4.11) (7.56) (16.56) (14.54) 4.31 (5.21) (4.87) (33.9) pt
People
People Employees — — 96 135 201 345 543 610 761 883 — +37.3%
Revenue/emp, $m — 0.00 0.24 0.38 0.31 0.27 0.25 0.36 0.44 0.39 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Castle Biosciences, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NEO NeoGenomics, Inc. $2.1B — (loss-making) — (loss-making) +11.43% (above 0%: growing) n/m −3,724.21% (below 0%: shrinking) 46.16% (3.79%) Compare
VCYT Veracyte, Inc. $1.9B 15.2× 45.2× +15.08% (above 0%: growing) +62.50% (above 0%: growing) −9.63% (below 0%: shrinking) 70.58% 10.92% Compare
WGS GeneDx Holdings Corp. $1.9B — (loss-making) — (loss-making) +11.44% (above 0%: growing) n/m −585.59% (below 0%: shrinking) 68.37% (15.25%) Compare
PSNL Personalis, Inc. $1.7B — (loss-making) — (loss-making) +76.59% (above 0%: growing) n/m −15.54% (below 0%: shrinking) 25.67% (138.76%) Compare
OPK OPKO Health, Inc. $1.3B — (loss-making) — (loss-making) −56.87% (below 0%: shrinking) n/m −3.40% (below 0%: shrinking) 64.30% (48.02%) Compare
FRNM Freenome, Inc $1.1B — (loss-making) — — n/m +12.06% (above 0%: growing) — 0.00% Compare
CSTL Castle Biosciences, Inc. $1.0B — (loss-making) — (loss-making) +23.90% (above 0%: growing) n/m +56.82% (above 0%: growing) 76.75% (2.65%)
MYGN Myriad Genetics, Inc. $601.6M — (loss-making) — (loss-making) −10.51% (below 0%: shrinking) n/m +43.90% (above 0%: growing) 66.60% (20.40%) Compare
FLGT Fulgent Genetics, Inc. $513.4M — (loss-making) — (loss-making) +7.54% (above 0%: growing) n/m +2,058.74% (above 0%: growing) 35.33% (24.94%) Compare
Median of peers $1.5B — — +11.43% — −6.51% 64.30% (17.82%)

All 49 Diagnostics & Research stocks →

Pay and ownership Proxy statement filed 8 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 6.79m 13.17m 57.93
2024 6.94m 9.97m 39.69
2023 1.61m 779.82k 32.14
2022 7.55m 3.08m 35.06
2021 6.52m 2.13m 63.84

Ownership

Directors and executive officers, together 6.10%
BlackRock, Inc. 7.70%
RTW Investments, LP 7.00%
The Vanguard Group 6.00%
Principal Financial Group, Inc. 5.30%
Portloan Capital Management, LLC 5.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Castle Biosciences, Inc. (CSTL) Latest News

6 Nov

Impact 3 · · GuruFocus.com

5 Nov

Impact 3 · · MarketBeat
Impact 3 · · PR Newswire

28 Oct

Impact 3 · · PR Newswire

12 Oct

Impact 4 · · PR Newswire

9 Oct

Impact 4 · · Simply Wall St.

30 Sep

Impact 4 · · PR Newswire

28 Sep

Impact 3 · · PR Newswire

24 Sep

Impact 4 · · PR Newswire

22 Sep

Impact 4 · · PR Newswire

15 Sep

Impact 3 ·

9 Sep

Impact 4 ·

26 Aug

Impact 3 ·

13 Aug

Impact 4 · · MarketBeat

31 Jul

Impact 4 · transcript
Impact 3 · · Moby transcript

30 Jul

Impact 3 · · MarketBeat transcript
Impact 3 ·

14 Jul

Impact 4 ·

25 Jun

Impact 3 · · PR Newswire

16 Jun

Impact 4 ·

24 May

Impact 3 · · Simply Wall St.

12 May

Impact 3 · · PR Newswire

6 May

Impact 4 · · Moby
Impact 4 · · MarketBeat
Impact 4 · · PR Newswire
Impact 3 · · Zacks

5 May

Impact 4 · · Zacks

4 May

Impact 4 · · PR Newswire

21 Apr

Impact 4 ·
stockrow.com/CSTL · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com